对糖尿病性视网膜病变的并发症行玻璃体切割术时,眼内出血病例占15～28％。术中活动性出血,严重妨碍手术正常进行。因出血不可控制而过早终止手术者,达0.5～4％。本文是作者试用凝血酶控制术中眼内出血的报告。材料和方法:在39例增殖性糖尿病性视网膜病变需切割玻璃体的患者中,按计算机随机编目表确定的程序,对28例进行随机抽样双盲研究。在他们的眼压灌注液中,分别加入安慰剂或牛凝血酶(100单位/ml)。随机抽样结果,不让术者 Complications of diabetic retinopathy during vitrectomy, intraocular hemorrhage cases accounted for 15 to 28%. Intraoperative active bleeding, seriously hampered the normal operation. Due to uncontrollable bleeding and premature termination of surgery, up to 0.5 to 4%. This article is the author of the trial of thrombin intraocular hemorrhage control report. MATERIALS AND METHODS: In 39 patients with proliferative diabetic retinopathy requiring vitrectomy, a randomized double-blind study of 28 patients was performed according to a computer-based randomized cataloging procedure. In their intraocular perfusate, placebo or bovine thrombin (100 units / ml) was added. Random sampling results, not surgery